Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)DivestmentsFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BridgeBio Pharma (BBIO) Change in Cash (2019 - 2025)

BridgeBio Pharma's Change in Cash history spans 7 years, with the latest figure at -$73.0 million for Q4 2025.

  • For Q4 2025, Change in Cash fell 126.49% year-over-year to -$73.0 million; the TTM value through Dec 2025 reached -$111.1 million, down 138.51%, while the annual FY2025 figure was -$111.1 million, 138.51% down from the prior year.
  • Change in Cash for Q4 2025 was -$73.0 million at BridgeBio Pharma, up from -$106.0 million in the prior quarter.
  • Across five years, Change in Cash topped out at $275.4 million in Q4 2024 and bottomed at -$198.0 million in Q3 2021.
  • The 5-year median for Change in Cash is -$4.5 million (2022), against an average of $10.7 million.
  • The largest annual shift saw Change in Cash surged 2548.19% in 2021 before it plummeted 269.76% in 2025.
  • A 5-year view of Change in Cash shows it stood at $213.3 million in 2021, then plummeted by 132.3% to -$68.9 million in 2022, then plummeted by 87.82% to -$129.4 million in 2023, then surged by 312.79% to $275.4 million in 2024, then tumbled by 126.49% to -$73.0 million in 2025.
  • Per Business Quant, the three most recent readings for BBIO's Change in Cash are -$73.0 million (Q4 2025), -$106.0 million (Q3 2025), and $208.4 million (Q2 2025).